[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

20/20 Biolabs Inc (AIDX)

20/20 Biolabs Inc (AIDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,577
  • Shares Outstanding, K 12,251
  • Annual Sales, $ 2,050 K
  • Annual Income, $ -3,740 K
  • EBIT $ -2 M
  • EBITDA $ -2 M
  • 60-Month Beta N/A
  • Price/Sales 2.71
  • Price/Cash Flow N/A
  • Price/Book 1.86
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.28
  • Most Recent Earnings $-0.28 on 05/20/26
  • Next Earnings Date 08/19/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Services

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4011 +14.01%
on 07/30/26
0.6000 -23.78%
on 07/13/26
-0.1318 (-22.37%)
since 07/10/26
3-Month
0.4011 +14.01%
on 07/30/26
1.6600 -72.45%
on 05/12/26
-0.9127 (-66.62%)
since 05/08/26

Most Recent Stories

More News
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour

Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern...

AIDX : 0.4573 (+0.46%)
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

Management Met with Potential Acquisition, Licensing, Joint Venture, and Commercial Partners Across the Region Initiative Aims to Expand Mission of Saving Lives Through Early Detection and Prevention...

AIDX : 0.4573 (+0.46%)
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) --...

AIDX : 0.4573 (+0.46%)
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth

Company Outlines Strategy to Position OneTest™ as the First Affordable, Multi-Cancer Early Detection Blood Test for Earlier Stage Detection GAITHERSBURG, Md., July 09, 2026 (GLOBE NEWSWIRE) --...

AIDX : 0.4573 (+0.46%)
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month

Inaugural Session to be Held Wednesday, July 1, 2026, at 12:00 p.m. ET Recurring Forum Intended to Increase Transparency, Strengthen Shareholder Communication, and Provide Investors with Direct Access...

AIDX : 0.4573 (+0.46%)
20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First Cohort GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20...

AIDX : 0.4573 (+0.46%)
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand

Company to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if Needed  GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs , Inc. (Nasdaq: AIDX)...

AIDX : 0.4573 (+0.46%)
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress

State-Funded Firefighter Cancer Screening Programs Expected to Drive Meaningful Revenue Growth Beginning in Q2 2026 $5.0 Million Private Placement Strengthens Cash Position to $4.2 Million as of March...

AIDX : 0.4573 (+0.46%)
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026

GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection...

AIDX : 0.4573 (+0.46%)
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina

Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs’ AI-Enabled Multi-Cancer Early...

AIDX : 0.4573 (+0.46%)

Business Summary

20/20 BioLabs Inc. is an early market in cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. 20/20 BioLabs Inc. is based in GAITHERSBURG, Md.

See More

Key Turning Points

3rd Resistance Point 0.5124
2nd Resistance Point 0.4924
1st Resistance Point 0.4749
Last Price 0.4573
1st Support Level 0.4374
2nd Support Level 0.4174
3rd Support Level 0.3999

See More

52-Week High 50.0000
Fibonacci 61.8% 31.0532
Fibonacci 50% 25.2006
Fibonacci 38.2% 19.3479
Last Price 0.4573
52-Week Low 0.4011

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.